CTLA4 (BALB/c)

Immunotherapy, cancer research, drug screening

Validation Data

Figure 1. Expression of CTLA4 in the activated spleen lymphocytes of homozygous humanized CTLA4 BALB/c KI mice is detected by FACS.

Figure 2. In vivo validation of homozygous BALB/c-hCTLA4 mice. The homozygous BALB/c-hCTLA4 mice were inoculated with CT26 cells, and randomly assigned to different groups (n=7) when the tumor grew to a volume of 100 mm3. A combinatorial treatment of anti-hCTLA4 antibody Yervoy and entinostat (ENT, a class I HDAC inhibitor) demonstrated a noticeable efficacy improvement compared to the same dose of single agent (A) without affecting the animal body weight (B).

Figure 3. In vivo validation of homozygous BALB/c-hCTLA4 mice. The homozygous BALB/c-hCTLA4 mice were inoculated with H22 cells, and randomly assigned to different groups (n=7) when the tumor grew to a volume of 100 mm3. Treatment of anti-hCTLA4 antibody Yervoy and Teremelimumab can effectively control tumor growth in BALB/c-hCTLA4 mice (A) without affecting the animal body weight (B).